Cargando…

Low-dose nivolumab in advanced hepatocellular carcinoma

BACKGROUND: The approved dose of nivolumab is 3 mg/kg or a flat dose of 240 mg for indications. There is no dose-response relationship for nivolumab; therefore, a low-dose regimen may be an option to reduce financial toxicity. This study was designed to investigate the efficacy and safety of low-dos...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Yen-Hao, Wang, Chih-Chi, Chen, Yen-Yang, Wang, Jing-Houng, Hung, Chao-Hung, Kuo, Yuan-Hung
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9644453/ https://www.ncbi.nlm.nih.gov/pubmed/36348292 http://dx.doi.org/10.1186/s12885-022-10271-6

Ejemplares similares

Real-world comparison of pembrolizumab and nivolumab in advanced hepatocellular carcinoma
por: Chen, Yen-Hao, et al.
Publicado: (2023)

Nivolumab Versus Regorafenib in Patients With Hepatocellular Carcinoma After Sorafenib Failure
por: Kuo, Yuan-Hung, et al.
Publicado: (2021)

Real-World Lenvatinib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis
por: Kuo, Yuan-Hung, et al.
Publicado: (2021)

Corrigendum: Real-World Lenvatinib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis
por: Kuo, Yuan-Hung, et al.
Publicado: (2021)

The Prognostic Value of Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio in Patients with Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab
por: Wang, Jing-Houng, et al.
Publicado: (2022)

Well-Controlled Viremia Predicts the Outcome of Hepatocellular Carcinoma in Chronic Viral Hepatitis Patients Treated with Sorafenib
por: Kuo, Yuan-Hung, et al.
Publicado: (2022)

Predicting outcomes for recurrent hepatocellular carcinoma within Milan criteria after complete radiofrequency ablation
por: Chen, Hsin-Yeh, et al.
Publicado: (2020)

Hepatic Clostridium Perfringens Abscess Formation after Radiofrequency Ablation Therapy for Hepatocellular Carcinoma: Report of a Rare Case
por: Wang, Ming-Hung, et al.
Publicado: (2021)

Modifiable Prognostic Factors of Hepatocellular Carcinoma in Patients with Non-Surgical Treatment
por: Yeh, Jen-Hao, et al.
Publicado: (2015)

Comparisons of Viral Etiology and Outcomes of Hepatocellular Carcinoma Undergoing Liver Resection between Taiwan and Vietnam
por: Nguyen-Dinh, Song-Huy, et al.
Publicado: (2022)

Nomogram to Predict the Long-Term Overall Survival of Early-Stage Hepatocellular Carcinoma after Radiofrequency Ablation
por: Kuo, Yuan-Hung, et al.
Publicado: (2023)

Lenvatinib combined with nivolumab in advanced hepatocellular carcinoma-real-world experience
por: Wu, Wen-Chi, et al.
Publicado: (2022)

Short Half-Life of Des-γ-Carboxy Prothrombin Is a Superior Factor for Early Prediction of Outcomes of Hepatocellular Carcinoma Treated with Radiofrequency Ablation
por: Yao, Chih-Chien, et al.
Publicado: (2023)

Tumor Lysis Syndrome after Combination Therapy of Nivolumab and Sorafenib in a Woman with Advanced Hepatocellular Carcinoma
por: Yen, Tsai-Hung, et al.
Publicado: (2020)

Real world clinical practice in treating advanced hepatocellular carcinoma: When East meets West
por: Yen, Yi-Hao, et al.
Publicado: (2020)

Active hepatocellular carcinoma is an independent risk factor of direct-acting antiviral treatment failure: A retrospective study with prospectively collected data
por: Yen, Yi-Hao, et al.
Publicado: (2019)

Predictive Effects of Inflammatory Scores in Patients with BCLC 0-A Hepatocellular Carcinoma after Hepatectomy
por: Huang, Pao-Yuan, et al.
Publicado: (2019)

Serial changes of clinical parameters in a patient with advanced hepatocellular carcinoma with portal vein thrombosis achieving complete response after treatment with sorafenib
por: Kee, Kwong-Ming, et al.
Publicado: (2014)

Artificial intelligence-based immunoprofiling serves as a potentially predictive biomarker of nivolumab treatment for advanced hepatocellular carcinoma
por: Lee, Jan-Mou, et al.
Publicado: (2022)

Characteristics and etiologies of hepatocellular carcinoma in patients without cirrhosis: When East meets West
por: Yen, Yi-Hao, et al.
Publicado: (2021)

Prognosis after resection of single large hepatocellular carcinoma: Results from an Asian high-volume liver surgery center
por: Liu, Yueh-Wei, et al.
Publicado: (2020)

HBcrAg Predicts Hepatocellular Carcinoma Development in Chronic B Hepatitis Related Liver Cirrhosis Patients Undergoing Long-Term Effective Anti-Viral
por: Chang, Kuo-Chin, et al.
Publicado: (2022)

Real-World Comparative Effectiveness of Nivolumab versus Pembrolizumab in Patients with Unresectable Hepatocellular Carcinoma
por: Kuo, Hsin-Yu, et al.
Publicado: (2022)

Ultrasound is highly specific in diagnosing compensated cirrhosis in chronic hepatitis C patients in real world clinical practice
por: Yen, Yi-Hao, et al.
Publicado: (2019)

A Randomized Controlled Trial of Glycyrrhizin Plus Tenofovir vs. Tenofovir in Chronic Hepatitis B with Severe Acute Exacerbation
por: Hung, Chao-Hung, et al.
Publicado: (2017)

Elevated levels of serum urokinase plasminogen activator predict poor prognosis in hepatocellular carcinoma after resection
por: Tsai, Ming-Chao, et al.
Publicado: (2019)

A Mac-2 Binding Protein Glycosylation Isomer-Based Risk Model Predicts Hepatocellular Carcinoma in HBV-Related Cirrhotic Patients on Antiviral Therapy
por: Chen, Chien-Hung, et al.
Publicado: (2022)

Significance of Vitamin D Receptor Gene Polymorphisms for Risk of Hepatocellular Carcinoma in Chronic Hepatitis C
por: Hung, Chao-Hung, et al.
Publicado: (2014)

Adherence to the modified Barcelona Clinic Liver Cancer guidelines: Results from a high-volume liver surgery center in East Asias
por: Yen, Yi-Hao, et al.
Publicado: (2021)

Causes of Death among Patients with Hepatocellular Carcinoma According to Chronic Liver Disease Etiology
por: Yen, Yi-Hao, et al.
Publicado: (2023)

Dynamic noninvasive markers predict hepatocellular carcinoma in chronic hepatitis C patients without sustained virological response after interferon-based therapy: Prioritize who needs urgent direct-acting antiviral agents
por: Huang, Chao-Min, et al.
Publicado: (2017)

Impact of MAFLD on HBV-Related Stage 0/A Hepatocellular Carcinoma after Curative Resection
por: Lin, Yen-Po, et al.
Publicado: (2021)

A scoring system to predict HBsAg seroclearance in hepatitis B and C coinfected patients treated with interferon and ribavirin in an Asian cohort
por: Yen, Yi-Hao, et al.
Publicado: (2018)

Peripheral blood toll-like receptor 4 correlates with rapid virological response to pegylated-interferon and ribavirin therapy in hepatitis C genotype 1 patients
por: Lee, Chuan-Mo, et al.
Publicado: (2016)

Sustained virological response and metabolic risk factors are associated with mortality in patients with chronic hepatitis C
por: Yen, Yi-Hao, et al.
Publicado: (2019)

APRI and FIB-4 in the evaluation of liver fibrosis in chronic hepatitis C patients stratified by AST level
por: Yen, Yi-Hao, et al.
Publicado: (2018)

Prediction model of hepatocellular carcinoma risk in Asian patients with chronic hepatitis B treated with entecavir
por: Chen, Chien-Hung, et al.
Publicado: (2017)

Maintenance therapy of low-dose nivolumab, S-1, and leucovorin in metastatic pancreatic adenocarcinoma with a germline mutation of MSH6: A case report
por: Peng, Shang-Hsuan, et al.
Publicado: (2022)

Prognosticators of hepatocellular carcinoma with intrahepatic vascular invasion
por: Lo, Yuan-Chen, et al.
Publicado: (2019)

Immune Checkpoint Inhibitor, Nivolumab, Combined with Chemotherapy Improved the Survival of Unresectable Advanced and Metastatic Esophageal Squamous Cell Carcinoma: A Real-World Experience
por: Kao, Ming-Wei, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_j6juu0djrs80elnugt1gp7h6p9